Legal Representation
Attorney
Michael T. Smith
USPTO Deadlines
Next Deadline
855 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-11-23)
Due Date
November 23, 2027
Grace Period Ends
May 23, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
33 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 19, 2022 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Nov 23, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Oct 22, 2021 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Oct 21, 2021 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Oct 5, 2021 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Oct 4, 2021 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Sep 20, 2021 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Sep 20, 2021 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Apr 20, 2021 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Feb 23, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 23, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 3, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 14, 2021 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 5, 2021 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Jan 5, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 5, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 1, 2020 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Dec 1, 2020 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Dec 1, 2020 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Oct 26, 2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 25, 2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Oct 25, 2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 25, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Sep 25, 2020 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Sep 25, 2020 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Sep 13, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 26, 2020 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Aug 26, 2020 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Aug 26, 2020 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
| Aug 26, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jul 9, 2020 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Jul 8, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 13, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
biological preparations, other than for medical or veterinary purposes, for use in cell cultures; biological preparations, other than for medical or veterinary purposes, for production of protein; biological material for producing protein for manufacturing use; Cells, vectors and expression systems for producing proteins for manufacturing use
First Use Anywhere:
Jun 22, 2021
First Use in Commerce:
Jun 22, 2021
Class 005
biological preparations for medical purposes, for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; biological material for producing medical protein; Cells, vectors and expression systems for producing medical proteins; biological preparations for veterinary purposes for treatment of canine disease; biological preparations for producing protein for treatment of veterinary disease
First Use Anywhere:
Jun 22, 2021
First Use in Commerce:
Jun 25, 2021
Class 042
product development for others; pharmaceutical drug development services; scientific research and development; pharmaceutical research; research and development of new products; Consulting services in the field of pharmaceutical technology development; biochemical research and analysis; research services for biomedical science; pharmaceutical preparations and medicines development; research and development of antibodies
First Use Anywhere:
Jun 22, 2021
First Use in Commerce:
Jun 25, 2021
Additional Information
Design Mark
The mark consists of the stylized wording "WUXIA" in black; above the wording are two Chinese characters in blue; underneath the wording is a line punctuated by a leg of the letter "X" with the colors in the line from left to right being blue, green and yellow.
Color Claim
The color(s) blue, black, green, and yellow is/are claimed as a feature of the mark.
Other
The non-Latin characters in the mark transliterate to "WUXIA" and this means "flawless" in English.
Classification
International Classes
001
005
042